GSK-CureVac's 2nd Covid Vax Shows Better Immune Response Against Beta, Delta And Lambda Variants

CureVac's first mRNA-based Covid vaccine CVnCoV, showed efficacy of just 47 per cent, the lowest reported so far from any Covid-19 vaccine maker.

from Top Lifestyle News- News18.com https://ift.tt/2W2zSLr